These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 28186762

  • 1. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).
    Kumar V, Moritz AE, Keck TM, Bonifazi A, Ellenberger MP, Sibley CD, Free RB, Shi L, Lane JR, Sibley DR, Newman AH.
    J Med Chem; 2017 Feb 23; 60(4):1478-1494. PubMed ID: 28186762
    [Abstract] [Full Text] [Related]

  • 2. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
    Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, Sibley DR.
    Eur Neuropsychopharmacol; 2015 Sep 23; 25(9):1448-61. PubMed ID: 25583363
    [Abstract] [Full Text] [Related]

  • 3. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V.
    Expert Opin Drug Discov; 2016 Jul 23; 11(7):641-64. PubMed ID: 27135354
    [Abstract] [Full Text] [Related]

  • 4. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P, Xie B, Semeano A, Bonifazi A, Battiti FO, Newman AH, Yano H, Shi L.
    Biomolecules; 2021 Apr 13; 11(4):. PubMed ID: 33924613
    [Abstract] [Full Text] [Related]

  • 5. Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores.
    Reilly SW, Griffin S, Taylor M, Sahlholm K, Weng CC, Xu K, Jacome DA, Luedtke RR, Mach RH.
    J Med Chem; 2017 Dec 14; 60(23):9905-9910. PubMed ID: 29125762
    [Abstract] [Full Text] [Related]

  • 6. Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D3 Dopamine Receptor.
    Moritz AE, Bonifazi A, Guerrero AM, Kumar V, Free RB, Lane JR, Verma RK, Shi L, Newman AH, Sibley DR.
    ACS Chem Neurosci; 2020 Oct 21; 11(20):3309-3320. PubMed ID: 32969645
    [Abstract] [Full Text] [Related]

  • 7. The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists.
    Battiti FO, Cemaj SL, Guerrero AM, Shaik AB, Lam J, Rais R, Slusher BS, Deschamps JR, Imler GH, Newman AH, Bonifazi A.
    J Med Chem; 2019 Jul 11; 62(13):6287-6314. PubMed ID: 31257877
    [Abstract] [Full Text] [Related]

  • 8. Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D3 Receptor Antagonists and Partial Agonists.
    Shaik AB, Kumar V, Bonifazi A, Guerrero AM, Cemaj SL, Gadiano A, Lam J, Xi ZX, Rais R, Slusher BS, Newman AH.
    J Med Chem; 2019 Oct 24; 62(20):9061-9077. PubMed ID: 31526003
    [Abstract] [Full Text] [Related]

  • 9. Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3 receptors.
    Fasciani I, Pietrantoni I, Rossi M, Mannoury la Cour C, Aloisi G, Marampon F, Scarselli M, Millan MJ, Maggio R.
    Eur J Pharmacol; 2018 Jan 15; 819():181-189. PubMed ID: 29223348
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y, Min C, Acharya S, Kim KM, Cheon SH.
    Bioorg Med Chem; 2016 Jan 15; 24(2):191-200. PubMed ID: 26707842
    [Abstract] [Full Text] [Related]

  • 11. High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice.
    Boateng CA, Bakare OM, Zhan J, Banala AK, Burzynski C, Pommier E, Keck TM, Donthamsetti P, Javitch JA, Rais R, Slusher BS, Xi ZX, Newman AH.
    J Med Chem; 2015 Aug 13; 58(15):6195-213. PubMed ID: 26203768
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents.
    Cai J, Huang M, Wang Y, Chen X, Ji M.
    Bioorg Med Chem Lett; 2021 Sep 15; 48():128269. PubMed ID: 34284107
    [Abstract] [Full Text] [Related]

  • 13. Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands.
    Keck TM, Banala AK, Slack RD, Burzynski C, Bonifazi A, Okunola-Bakare OM, Moore M, Deschamps JR, Rais R, Slusher BS, Newman AH.
    Bioorg Med Chem; 2015 Jul 15; 23(14):4000-12. PubMed ID: 25650314
    [Abstract] [Full Text] [Related]

  • 14. Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptor.
    Shonberg J, Draper-Joyce C, Mistry SN, Christopoulos A, Scammells PJ, Lane JR, Capuano B.
    J Med Chem; 2015 Jul 09; 58(13):5287-307. PubMed ID: 26052807
    [Abstract] [Full Text] [Related]

  • 15. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors.
    Silvano E, Millan MJ, Mannoury la Cour C, Han Y, Duan L, Griffin SA, Luedtke RR, Aloisi G, Rossi M, Zazzeroni F, Javitch JA, Maggio R.
    Mol Pharmacol; 2010 Nov 09; 78(5):925-34. PubMed ID: 20702763
    [Abstract] [Full Text] [Related]

  • 16. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH, Beuming T, Banala AK, Donthamsetti P, Pongetti K, LaBounty A, Levy B, Cao J, Michino M, Luedtke RR, Javitch JA, Shi L.
    J Med Chem; 2012 Aug 09; 55(15):6689-99. PubMed ID: 22632094
    [Abstract] [Full Text] [Related]

  • 17. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors.
    Saavedra OM, Karila D, Brossard D, Rojas A, Dupuis D, Gohier A, Mannoury la Cour C, Millan MJ, Ortuno JC, Hanessian S.
    Bioorg Med Chem; 2017 Jan 01; 25(1):38-52. PubMed ID: 28029458
    [Abstract] [Full Text] [Related]

  • 18. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.
    Kumar V, Bonifazi A, Ellenberger MP, Keck TM, Pommier E, Rais R, Slusher BS, Gardner E, You ZB, Xi ZX, Newman AH.
    J Med Chem; 2016 Aug 25; 59(16):7634-50. PubMed ID: 27508895
    [Abstract] [Full Text] [Related]

  • 19. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.
    Verma RK, Abramyan AM, Michino M, Free RB, Sibley DR, Javitch JA, Lane JR, Shi L.
    PLoS Comput Biol; 2018 Jan 25; 14(1):e1005948. PubMed ID: 29337986
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S, Saini SK, Zhou G, Hobrath JV, Padmalayam I, Zhai L, Bostwick JR, Antonio T, Reith ME, McDowell S, Cho E, McAleer L, Taylor M, Luedtke RR.
    J Med Chem; 2014 Aug 28; 57(16):7042-60. PubMed ID: 25126833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.